Researchers report that 48 percent of high-dose patients and 46 percent of low-dose patients achieved treatment success, which is defined as the person’s ability to consume at least 10 times more peanut protein than they could before starting the trial. Participants were given patches containing either a high-dose of peanut protein, a low-dose, or a placebo. Researchers studied the effects of the EPIT patch on 74 people, between the ages of 4 and 25, with peanut allergies. “One goal of experimental approaches such as epicutaneous immunotherapy is to reduce this burden by training the immune system to tolerate enough peanut to protect against accidental ingestion or exposure,” said NIAID Director, Dr. In general, people with food allergies must be highly cautious about the foods they eat and places they go in order to avoid allergens. The treatment is called epicutaneous immunotherapy (EPIT), and consists of a simple skin patch that people apply daily to their arm or between their shoulder blades.
0 kommentar(er)
